Pasar al contenido principal

-

FPDI-2013-16409

•
Nombre agencia financiadora Ministerio de Ciencia e Innovación
Acrónimo agencia financiadora MICINN
Programa Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprograma Subprograma Estatal de Formación
Convocatoria Contratos para la Formación Posdoctoral
Año convocatoria 2013
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Secretaría de Estado de Educación, Formación Profesional y Universidades
Centro beneficiario FUNDACION PARA LA INVEST. BIOMEDICA DEL HOSPITAL UNIV. DOCE DE OCTUBRE
Identificador persistente http://dx.doi.org/10.13039/501100004837

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Docta Complutense
Publicación Artículo científico (JournalArticle)

Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapse

  • Onecha, Esther
  • Rapado, Inmaculada
  • Morales, Maria Luz
  • Carreño-Tarragona, Gonzalo
  • Martínez-Sánchez, Pilar
  • Gutiérrez, Xavier
  • Sánchez Pina, José María
  • Linares Gómez, María
  • Gallardo, Miguel
  • Martínez López, Joaquín
  • Ayala Díaz, Rosa María
In cases of treatment failure in acute myeloid leukemia (AML), the utility of mutational profiling in primary refractoriness and relapse is not established. We undertook a perspective study using next-generation sequencing (NGS) of clinical follow-up samples (n=91) from 23 patients with AML with therapeutic failure to cytarabine plus idarubicin or fludarabine. Cases of primary refractoriness to treatment were associated with a lower number of DNA variants at diagnosis than cases of relapse (median 1.67 and 3.21, respectively, p=0.029). The most frequently affected pathways in patients with primary refractoriness were signaling, transcription and tumor suppression, whereas methylation and splicing pathways were mainly implicated in relapsed patients. New therapeutic targets, either by an approved drug or within clinical trials, were not identified in any of the cases of refractoriness (0/10); however, 8 potential new targets were found in 5 relapsed patients (5/13) (p=0.027): 1 IDH2, 3 SF3B1, 2 KRAS, 1 KIT and 1 JAK2. Sixty-five percent of all variants detected at diagnosis were not detected at complete response (CR). Specifically, 100% of variants in EZH2, RUNX1, VHL, FLT3, ETV6, U2AF1, PHF6 and SF3B1 disappeared at CR, indicating their potential use as markers to evaluate minimal residual disease (MRD) for follow-up of AML. Molecular follow-up using a custom NGS myeloid panel of 32 genes in the post-treatment evaluation of AML can help in the stratification of prognostic risk, the selection of MRD markers to monitor the response to treatment and guide post-remission strategies targeting AML, and the selection of new drugs for leukemia relapse.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Plasmodium species differentiation by non-expert on-line volunteers for remote malaria field diagnosis

  • Ortiz-Ruiz, Alejandra
  • Postigo, María
  • Gil-Casanova, Sara
  • Cuadrado, Daniel
  • Bautista Santa Cruz, José Manuel
  • Rubio, José Miguel
  • Luengo-Oroz, Miguel
  • Linares Gómez, María
Background: Routine feld diagnosis of malaria is a considerable challenge in rural and low resources endemic areas mainly due to lack of personnel, training and sample processing capacity. In addition, diferential diagnosis of Plasmodium species has a high level of misdiagnosis. Real time remote microscopical diagnosis through on-line crowdsourc‑ing platforms could be converted into an agile network to support diagnosis-based treatment and malaria control in low resources areas. This study explores whether accurate Plasmodium species identifcation—a critical step during the diagnosis protocol in order to choose the appropriate medication—is possible through the information provided by non-trained on-line volunteers. Methods: 88 volunteers have performed a series of questionnaires over 110 images to diferentiate species (Plasmodium falciparum, plasmodium ovale, Plasmodium vivax, Plasmodium malariae, Plasmodium knowlesi) and parasite stag‑ ing from thin blood smear images digitalized with a smartphone camera adapted to the ocular of a conventional light microscope. Visual cues evaluated in the surveys include texture and colour, parasite shape and red blood size. Results: On-line volunteers are able to discriminate Plasmodium species (P. falciparum, P. malariae, P. vivax, P. ovale, P. knowlesi) and stages in thin-blood smears according to visual cues observed on digitalized images of parasitized red blood cells. Friendly textual descriptions of the visual cues and specialized malaria terminology is key for volunteers learning and efciency. Conclusions: On-line volunteers with short-training are able to diferentiate malaria parasite species and parasite stages from digitalized thin smears based on simple visual cues (shape, size, texture and colour). While the accuracy of a single on-line expert is far from perfect, a single parasite classifcation obtained by combining the opinions of multiple on-line volunteers over the same smear, could improve accuracy and reliability of Plasmodium species identifcation in remote malaria diagnosis.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Collaborative intelligence and gamification for on-line malaria species differentiation

  • Linares Gómez, María
  • Postigo, María
  • Cuadrado, Daniel
  • Ortiz-Ruiz, Alejandra
  • Gil-Casanova, Sara
  • Vladimirov, Alexander
  • García-Villena, Jaime
  • Nuñez-Escobedo, José María
  • Martínez López, Joaquín
  • Rubio, José Miguel
  • Ledesma-Carbayo, María Jesús
  • Santos, Andrés
  • Bassat, Quique
  • Luengo-Oroz, Miguel
Background: Current World Health Organization recommendations for the management of malaria include the need for a parasitological confrmation prior to triggering appropriate treatment. The use of rapid diagnostic tests (RDTs) for malaria has contributed to a better infection recognition and a more targeted treatment. Nevertheless, low-density infections and parasites that fail to produce HRP2 can cause false-negative RDT results. Microscopy has traditionally been the methodology most commonly used to quantify malaria and characterize the infecting species, but the wider use of this technique remains challenging, as it requires trained personnel and processing capacity. Objective: In this study, the feasibility of an on-line system for remote malaria species identifcation and diferentia‑ tion has been investigated by crowdsourcing the analysis of digitalized infected thin blood smears by non-expert observers using a mobile app. Methods: An on-line videogame in which players learned how to diferentiate the young trophozoite stage of the fve Plasmodium species has been designed. Images were digitalized with a smartphone camera adapted to the ocular of a conventional light microscope. Images from infected red blood cells were cropped and puzzled into an on-line game. During the game, players had to decide the malaria species (Plasmodium falciparum, Plasmodium malariae, Plasmodium vivax, Plasmodium ovale, Plasmodium knowlesi) of the infected cells that were shown in the screen. After 2 months, each player’s decisions were analysed individually and collectively. Results: On-line volunteers playing the game made more than 500,000 assessments for species diferentiation. Statistically, when the choice of several players was combined (n>25), they were able to signifcantly discriminate Plasmodium species, reaching a level of accuracy of 99% for all species combinations, except for P. knowlesi (80%). Non-expert decisions on which Plasmodium species was shown in the screen were made in less than 3 s. Conclusion: These fndings show that it is possible to train malaria-naïve non-experts to identify and diferentiate malaria species in digitalized thin blood samples. Although the accuracy of a single player is not perfect, the combination of the responses of multiple casual gamers can achieve an accuracy that is within the range of the diagnostic accuracy made by a trained microscopist.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity

  • Onecha, Esther
  • Ruiz‐Heredia, Yanira
  • Martínez‐Cuadrón, David
  • Barragán, Eva
  • Martínez Sánchez, María Del Pilar
  • Linares Gómez, María
  • Rapado, Inmaculada
  • Perez‐Oteyza, Jaime
  • Magro, Elena
  • Herrera, Pilar
  • Rojas, José Luis
  • Gorrochategui, Julián
  • Villoria, Jesús
  • Boluda, Blanca
  • Sargas, Claudia
  • Ballesteros, Joan
  • Montesinos, Pau
  • Martínez López, Joaquín
  • Ayala Díaz, Rosa María
Refractoriness to induction therapy and relapse after complete remission are the leading causes of death in patients with acute myeloid leukaemia (AML). This study focussed on the prediction of response to standard induction therapy and outcome of patients with AML using a combined strategy of mutational profiling by next-generation sequencing (NGS, n = 190) and ex vivo PharmaFlow testing (n = 74) for the 10 most widely used drugs for AML induction therapy, in a cohort of adult patients uniformly treated according to Spanish PETHEMA guidelines. We identified an adverse mutational profile (EZH2, KMT2A, U2AF1 and/or TP53 mutations) that carries a greater risk of death [hazard ratio (HR): 3 29, P < 0 0001]. A high correlation was found between the ex vivo PharmaFlow results and clinical induction response (69%). Clinical correlation analysis showed that the pattern of multiresistance revealed by ex vivo PharmaFlow identified patients with a high risk of death (HR: 2 58). Patients with mutation status also ran a high risk (HR 4 19), and the risk was increased further in patients with both adverse profiles (HR 4 82). We have developed a new score based on NGS and ex vivo drug testing for AML patients that improves upon current prognostic risk stratification and allows clinicians to tailor treatments to minimise drug resistance.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia

  • Onecha, Esther
  • Linares, Maria
  • Rapado, Inmaculada
  • Ruiz-Heredia, Yanira
  • Martínez Sánchez, Pilar|||0000-0002-7334-140X
  • Cedena, Teresa
  • Pratcorona, Marta|||0000-0001-6375-596X
  • Oteyza, Jaime Perez
  • Herrera, Pilar|||0000-0002-4118-7110
  • Barragán, Eva
  • Montesinos, Pau|||0000-0002-3275-5593
  • Vela, Jose Antonio Garcia
  • Magro, Elena
  • Anguita, Eduardo|||0000-0003-1386-4943
  • Figuera, Angela
  • Riaza, Rosalia
  • Martinez-Barranco, Pilar
  • Sanchez-Vega, Beatriz
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Gallardo, Miguel
  • Martínez-López, Joaquín|||0000-0001-7908-0063
  • Ayala, Rosa|||0000-0002-2699-8353
A high proportion of patients with acute myeloid leukemia who achieve minimal residual disease negative status ultimately relapse because a fraction of pathological clones remains undetected by standard methods. We designed and validated a high-throughput sequencing method for minimal residual disease assessment of cell clonotypes with mutations of NPM1, IDH1/2 and/or FLT3-single nucleotide variants. For clinical validation, 106 follow-up samples from 63 patients in complete remission were studied by sequencing, evaluating the level of mutations detected at diagnosis. The predictive value of minimal residual disease status by sequencing, multiparameter flow cytometry, or quantitative polymerase chain reaction analysis was determined by survival analysis. The sequencing method achieved a sensitivity of 10 for single nucleotide variants and 10 for insertions/deletions and could be used in acute myeloid leukemia patients who carry any mutation (86% in our diagnostic data set). Sequencing-determined minimal residual disease positive status was associated with lower disease-free survival (hazard ratio 3.4, P=0.005) and lower overall survival (hazard ratio 4.2, P<0.001). Multivariate analysis showed that minimal residual disease positive status determined by sequencing was an independent factor associated with risk of death (hazard ratio 4.54, P=0.005) and the only independent factor conferring risk of relapse (hazard ratio 3.76, P=0.012). This sequencing-based method simplifies and standardizes minimal residual disease evaluation, with high applicability in acute myeloid leukemia. It is also an improvement upon flow cytometry- and quantitative polymerase chain reaction-based prediction of outcomes of patients with acute myeloid leukemia and could be incorporated in clinical settings and clinical trials.